Glucagon News and Research

RSS

Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes

Researchers compare the weight loss efficacy of injectable liraglutide and semaglutide.

17 Sep 2024

Real-world data reveals factors associated with long-term weight loss in obesity

A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were prescribed injectable semaglutide or liraglutide for the treatment of type 2 diabetes or obesity. The study was published in JAMA Network Open.

14 Sep 2024

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the need for additional studies.

13 Sep 2024

GLP-2 regulates appetite by influencing gut-brain communication and gastrointestinal motility

Researchers examine the role of GLP-2 in regulating food intake through its effects on gastrointestinal motility and satiety signals, offering insights into potential obesity treatments.

12 Sep 2024

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.

12 Sep 2024

Women experience greater weight loss with tirzepatide compared to men

All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

11 Sep 2024

Obesity medication liraglutide safe and effective in children under 12, research finds

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found.

10 Sep 2024

Once-a-day oral weight loss drug shows promising results in reducing body weight

Individuals who received a once-a-day oral weight loss drug lost up to 13% of their body weight over three months, the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear.

10 Sep 2024

GLP-1 receptor agonists show promise in treating substance use disorders

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

9 Sep 2024

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year's annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

9 Sep 2024

Study shows beta cells can function independently for glycemic control

Our glycemic balance is based on the ability of the pancreatic beta cells to detect glucose and secrete insulin to maintain our blood sugar levels. If these cells malfunction, the balance is broken, and diabetes develops.

3 Sep 2024

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

2 Sep 2024

Is semaglutide use during breastfeeding safe?

Researchers found no detectable levels of semaglutide in breast milk, suggesting minimal risk to breastfed infants, but highlighted the need for monitoring maternal nutrition and milk production.

2 Sep 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.

28 Aug 2024

Glucagon News and Research

Semaglutide vs. liraglutide: One-year weight loss efficacy in obesity and type 2 diabetes

Real-world data reveals factors associated with long-term weight loss in obesity

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

GLP-2 regulates appetite by influencing gut-brain communication and gastrointestinal motility

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

Women experience greater weight loss with tirzepatide compared to men

Obesity medication liraglutide safe and effective in children under 12, research finds

Once-a-day oral weight loss drug shows promising results in reducing body weight

GLP-1 receptor agonists show promise in treating substance use disorders

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

Study shows beta cells can function independently for glycemic control

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Is semaglutide use during breastfeeding safe?

ESC consensus statement highlights obesity's impact on cardiovascular disease

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

GLP-1 therapy boosts visceral fat metabolism, driving weight loss

Clarification urgently needed for detected signal of semaglutide-linked suicidal ideation

Understanding the health benefits of polyphenols through bitter taste receptors

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News